-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

622.O1.6 622. Lymphomas: Translational - Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas

Symposia: Lymphomas: Translational - Non-Genetic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Hodgkin lymphoma, Combination therapy, Antibody Therapy, Translational Research, Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Checkpoint Inhibitor, Diseases, Indolent lymphoma, Immune mechanism, Cell expansion, Treatment Considerations, Biological therapies, Aggressive lymphoma, Immunology, Immunotherapy, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Gene editing, Pathogenesis
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)
Moderators:
Erin M. Parry, MD, PhD, ARRAY(0xdc649d4) and Tanaya Shree, MD, PhD, Oregon Health and Sciences University
Disclosures:
Shree: Gilead Sciences: Other: Spouse's employment.

This session will describe a number of new novel mechanisms that lymphomas utilise to evade the immune system and will describe therapeutic strategies that might be useful in these settings.
4:00 PM

Katsuyoshi Takata, MD, PhD1, Hidekazu IIoka2*, Shuta Tomida, PhD3*, Yuting Liu4*, Shujiro Okuda4*, Hiroyuki Usuda5*, Takashi Kawasaki6*, Akihiro Kitadate, M.D., Ph.D.7, Naoto Takahashi, MD, PhD8, Gerben Duns, PhD9*, Yasuharu Sato, PhD10*, Christian Steidl, MD, PhD9 and Daisuke Ennishi, MD, PhD11

1Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
2Division of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, Japan., Niigata, Japan
3Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sci, Okayama, JPN
4Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Niigata, Japan
5Department of Pathology, Nagaoka Red Cross Hospital, Niigata, Japan., Nagaoka, Japan
6Department of Pathology, Niigata Cancer Centre Hospital, Niigata, Japan, Niigata, Japan
7Department of Hematology, Nephrology and Rheumatology, Akita University, Akita, Japan
8Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
9Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
10Department of Molecular Hematopathology, Okayama University, Okayama, Japan
11Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan

4:15 PM

Ivan Odak1*, Lennart Riemann2*, Samir Parekh, MD3 and Joshua Brody, MD1,4*

1Icahn School of Medicine at Mount Sinai, New York, NY
2Hannover Medical School, Hannover, Germany
3Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
4Tisch Cancer Institute, New York, NY

4:30 PM

Ferran Araujo-Ayala1,2*, Maria Ros2,3*, Mireia Bachiller, PhD4*, Raluca Alexandru5*, Pablo Mozas, MD, PhD6*, Salut Colell7*, Judith Mateos-Jaimez8*, Cristina López, PhD2,7*, María Villalba-Esparza, PhD5*, Ferran Nadeu, PhD7*, Andrea Rivero, MD9*, Cèlia Dobaño-López, PhD8*, Juan Garcia Valero, PhD2,7*, Neus Serrat, MD, PhD10*, Marta Gimenez-Alejandre, PhD7*, Ariadna Giró7*, Daniel J Hodson, MD-PhD11, Armando Lopez-Guillermo, MD6,12, Elias Campo, MD, PhD13, Dolors Colomer14,15*, Alba Maiques-Diaz7*, Jose Ignacio Martin-Subero, PhD7,16*, Silvia Bea7,14,17,18*, Laura Magnano, MD, PhD19*, Sonia Guedan20*, Carlos Eduardo De Andrea, MD, PhD5* and Patricia Perez Galan, PhD2,8*

1Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), Barcelona, ESP
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
3Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
4Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, ESP
5Clínica Universidad de Navarra, Pamplona, Spain
6Department of Hematology, ICAMS, Hospital Clínic de Barcelona, Barcelona, Spain
7Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain
8Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, ESP
9Department of Hematology, Hospital Clínic, Barcelona, Barcelona, Spain
10Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Bacelona, ESP
11Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
12University of Barcelona, Barcelona, Spain
13Hematopathology Section, Department of Pathology, Hospital Clínic of Barcelona, Barcelona, Spain
14Hematopathology Section, Pathology Department, Hospital Clínic de Barcelona, Barcelona, Spain
15Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain
16Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
17Universitat de Barcelona, Barcelona, Spain
18Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain
19Hospital Clínic de Barcelona, Barcelona, Spain
20Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), Barcelona, Spain

4:45 PM

Gabriele Varano, PhD1, Hiroshi Arima, MD, PhD2*, Nicara C Parr3*, Eleonora Sala4*, Marta Mangione4*, Karlo Mladenic5*, Gaia Morello6*, Federica Mainoldi7*, Silvia Brambillasca8*, Adrian Andronache3*, Vanna Imsirovic5*, Ciro Mercurio9*, Felix Wensveen10*, Bojan Polic, MD, PhD10*, Mirela Kuka4*, Claudio Tripodo11* and Stefano Casola, MD, PhD3

1IFOM-ETS, Milano, Italy
2Kyoto University, Kyoto, JPN
3IFOM-ETS, Milan, Italy
4Vita-Salute San Raffaele University, Milan, Italy
5University of Rijeka Faculty of Medicine, Rijeka, Croatia
6University of Palermo, Palermo, ITA
7IFOM ETS-The AIRC Institute of Molecular Oncology, Milano, Italy
8Experimental Therapeutics Program, IFOM-ETS, Milan, Italy
9IFOM-ETS, Milan, ITA
10University of Rijeka, Rijeka, Croatia
11University of Palermo, Palermo, Italy

5:00 PM

Cynthia K. Hahn, MD, PhD1,2,3, Gavin E. Hooper1,2*, Alexandra Forman, BSc1,2,4*, Gabriela Brunsting Hoffmann2*, Sam Sadigh, MD3,5*, Kun Huang, PhD2*, Erin M. Parry, MD, PhD1,2,3, John G. Doench, PhD1*, Jeremy M. Simon, PhD6,7*, Abner Louissaint, MD, PhD8* and Catherine J. Wu, MD1,3,9*

1Broad Institute of MIT and Harvard, Cambridge, MA
2Dana-Farber Cancer Institute, Boston, MA
3Harvard Medical School, Boston, MA
4Harvard Medical School, Cambridge, MA
5Department of Pathology, Brigham and Women's Hospital, Boston, MA
6Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
7Harvard T.H. Chan School of Public Health, Boston, MA
8Massachusetts General Hospital, Boston, MA
9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

5:15 PM

Seda S. Tolu, MD1, Ted B. Piorczynski, PhD2, Manuel Pazos II, MS, BS3*, Brian Estrella, PhD4*, Hua-Jay J Cherng, MD5, Barbara Pro, MD6 and Jennifer E. Amengual, MD7

1Division of Hematology & Oncology, Columbia University Irving Medical Center, New York City, NY
2Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY
3Columbia University Medical Center, NEW YORK, NY
4Division of Hematology and Oncology, Columbia University Irving Medical Center, New York
5Division of Hematology & Oncology, Columbia University Irving Medical Center, Long Island City, NY
6Lymphoma Program, Division of Hematology & Oncology, Columbia University, New York, NY
7Division of Hematology & Oncology, Columbia University Irving Medical Center, New York

*signifies non-member of ASH